# HER2CLIMB (NCT02614794)

> A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02614794
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Seagen Inc.
- Conditions: HER2 Positive Breast Cancer
- Interventions: tucatinib; capecitabine; trastuzumab; placebo
- Enrollment: 612
- Primary outcome: Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)

## Commentary we found

- YouTube: 86
- Podcasts: 56
- X threads: 19

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=her2climb-nct02614794

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02614794", "email": "<work email>"}; the inbox owner confirms by the emailed link.